- Home
- MNPR vs IIIV Comparison
MNPR vs IIIV Comparison
Compare MNPR & IIIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNPR | IIIV |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 531.6M | 565.5M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MNPR | IIIV |
|---|---|---|
| Price | $70.61 | $26.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $97.83 | $33.33 |
| AVG Volume (30 Days) | 191.8K | ★ 329.1K |
| Earning Date | 11-13-2025 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.56 |
| Revenue | N/A | ★ $213,158,000.00 |
| Revenue This Year | N/A | $8.32 |
| Revenue Next Year | N/A | $7.26 |
| P/E Ratio | ★ N/A | $188.00 |
| Revenue Growth | N/A | ★ 11.47 |
| 52 Week Low | $21.00 | $22.00 |
| 52 Week High | $105.00 | $33.97 |
Technical Indicators
Market Signals| Indicator | MNPR | IIIV |
|---|---|---|
| Relative Strength Index (RSI) | 41.11 | 54.25 |
| Support Level | $64.25 | $25.79 |
| Resistance Level | $74.34 | $26.72 |
| Average True Range (ATR) | 4.79 | 0.78 |
| MACD | -0.53 | 0.45 |
| Stochastic Oscillator | 31.45 | 89.45 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About IIIV i3 Verticals Inc.
i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.